William Korb Unloaded 10000 shares of Cambrex Corporation (NYSE:CBM) in an Insider Trade

Share with your friends










Submit

William Korb Unloaded 10000 shares of Cambrex Corporation in an Insider Trade-Transactions

William Korb Insider Sell Transaction

Cambrex Corporation (NYSE:CBM) director William Korb on the 20/11/2015 unloaded a total of 10,000 shares of the corporation that are worth about $501,800 U.S. Dollars. This is based on an average price per share of $50.2 U.S. Dollars. The probability of this trade staying a secret is quite small, with the director presently having ownership of 36,562 shares — that is 0.11 % of the market capitalization of the company. This sale was completed on 20/11/2015. A form filed with the U.S. Security and Exchange Commission and obtainable online here, discloses full details of the sale.

Cambrex Corp Stock Rating, Sentiment and Fundamentals

Five professional security analysts specializing in stock such as Cambrex Corp’s one, forecast a growth rate YOY of 15.00%. If the earnings per share is $2.13 for 2015, the price to earnings ratio of the New Jersey-based Cambrex Corp would be 23.56.

Rating & Sentiment
PsychSignal Social:SELL
Analysts Rating:BUY
Hedge Funds Sentiment:NEUTRAL
Stock Fundamentals
Earnings + FCF Trend:BUY
Sector/Industry Macro:BULLISH
Valuation Models:-
Technical Analysis
ST Trend:UP
MT Trend:UP
LT Trend:UP
OctaFinance Rating*:NEUTRAL

* Read How Our Stock Ratings System Works

Over the last 200 days, the Cambrex Corp’s stock price has seen a stable up move of 67.21 % and is now in a very strong and smooth uptrend. Taking in consideration our trend-following model and William Korb’s stock sell, we rate the stock “Neutral”.

Price Chart of Cambrex Corporation NYSE:CBM Stock

William Korb Unloaded 10000 shares of Cambrex Corporation in an Insider Trade-Stock-Price-Chart

Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations

Just as legendary traders (who include George Soros) noted, the highest risk-adjusted returns are made via a combination of both fundamental as well as technical analysis. This doesn’t look to be the case with Cambrex Corp’s stock.

Hedge Funds Ownership

In the last quarter 224 hedge funds and institutional investors owned shares of Cambrex Corp. In Q2 2015, this company had 89.38 % institutional ownership. That is a very high interest. Its up 0.32 % from previous quarter. These hedge funds increased the total shares they own by 89,884 to 28.18 million this quarter. A total of 41 funds opened new positions in Cambrex Corp and 71 increased their holdings. There were 30 funds that closed their positions and 88 that reduced them.

There are six hedge funds having the company in their Top 10. They are: Tfs Capital Llc, Truenorth Inc., Bogle Investment Management L P De, Arbor Capital Management Llc, Thomson Horstmann & Bryant Inc, Weber Alan W.

HEDGE-FUNDS-LIST-DATABASE-FREE

Tfs Capital Llc had the greatest investment with ownership of 200,517 shares as of Q2 2015 for 0.86% of the fund’s portfolio. Truenorth Inc. is another positive player possessing 117,479 shares of the company or 2.46% of their stocks portfolio. The stock is also 1.27% of the fund’s AUM. Further The Massachusetts-based fund Bogle Investment Management L P De have 1.01% of their stock portfolio invested in the company’s market cap for 307,826 shares. Arbor Capital Management Llc revealed it had acquired a stake worth 1.45% of the fund’s stock portfolio in Cambrex Corp. The Connecticut-based fund Thomson Horstmann & Bryant Inc is also optimistic about the firm, possessing 365,096 shares or 1.22% of their stock portfolio.

Cambrex Corporation NYSE:CBM Company Profile

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and, to a lesser extent, other fine chemicals. Cambrex has three operating segments, which are manufacturing facilities that have been aggregated as one reportable segment.

Company Website: Cambrex Corporation

Cambrex Corp was founded in Delaware on 1983-10-11. Cambrex Corp has 1117 employees. As of writing its market worth is: $1.58 billion and it has 32.26 million shares outstanding. Currently the company has 97.90% shareholders and the institutional ownership stands at 97.90%. The stock closed at $50.18 yesterday and it had average 2 days volume of 54771 shares. It is down from the 30 days average shares volume of 83571. Cambrex Corp has a 250 days low of $21.14 and a 250 days high of $54.52. The current price is above the 200 days Simple moving average. Cambrex Corp last issued its quarterly earnings report on 11/03/2015. The company reported 0.36 EPS for the quarter, above the consensus estimate of 0.34 by 0.02. The company had a revenue of 92.98 million for 9/30/2015 and 106.64 million for 6/30/2015. Therefore, the revenue was -13,656,000 down.

Cambrex Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.